Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016)

Anticancer Research

Volumn 31, Issue 3, 2011, Pages 789-795

  Lo, Yuan Hung ^a   Ho, Po Chun ^a   Zhao, Huajun ^a   Wang, Shao Chun ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; c ABL; EGFR; ErbB2; Imatinib; Lapatinib; RTK

Indexed keywords

ABELSON KINASE; IMATINIB; LAPATINIB;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE PROGRESSION; CONTROLLED STUDY; ENZYME INHIBITION; PRIORITY JOURNAL; PROTEIN TARGETING; RNA INTERFERENCE; SENSITIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; QUINAZOLINES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 79956119036     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2): 127-137, 2001.
2. Rusnak DW, Alligood KJ, Mullin RJ, Spehar GM, Arenas-Elliott C, Martin AM et al: Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif 40(4): 580-594, 2007.
3. Alvarez RH, Valero V and Hortobagyi GN: Emerging targeted therapies for breast cancer. J Clinical Oncol 28(20): 3366-3379, 2010.
4. Mendelsohn J and Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21(14): 2787-2799, 2003. (Pubitemid 46606324)
5. Gomez HL, Doval DC, Chavez MA, Ang PC, Aziz Z, Nag S et al: Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26(18): 2999-3005, 2008.
6. Kharbanda S, Yuan ZM, Weichselbaum R and Kufe D: Determination of cell fate by c-Abl activation in the response to DNA damage. Oncogene 17(25): 3309-3318, 1998. (Pubitemid 29043983)
7. Lin J, Sun T, Ji L, Deng W, Roth J, Minna J et al: Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS 1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1. Oncogene 26(49): 6989-6996, 2007. (Pubitemid 350014606)
8. Pendergast AM: The Abl family kinases: mechanisms of regulation and signaling. Adv Cancer Res 85: 51-100, 2002.
9. Plattner R and Pendergast AM: Activation and signaling of the Abl tyrosine kinase: bidirectional link with phosphoinositide signaling. Cell Cycle 2(4): 273-274, 2003.
10. Shaul Y: c-Abl: activation and nuclear targets. Cell Death Differ 7(1): 10-16, 2000.
11. Wang JY: Regulation of cell death by the Abl tyrosine kinase. Oncogene 19(49): 5643-5650, 2000.
12. Zhao H, Ou-Yang F, Chen IF, Hou MF, Yuan SS, Chang HL et al: Enhanced resistance to tamoxifen by the c-ABL protooncogene in breast cancer. Neoplasia 12(3): 214-223, 2010.
13. Birge RB, Fajardo JE, Mayer BJ and Hanafusa H: Tyrosine-phosphorylated epidermal growth factor receptor and cellular p130 provide high affinity binding substrates to analyze Crk-phosphotyrosine-dependent interactions in vitro. J Biol Chem 267(15): 10588-10595, 1992.
14. Tanos B and Pendergast AM: Abl tyrosine kinase regulates endocytosis of the epidermal growth factor receptor. J Biol Chem 281(43): 32714-32723, 2006. (Pubitemid 46036827)
15. Sims JT, Ganguly S, Fiore LS, Holler CJ, Park E-S and Plattner R: STI571 sensitizes breast cancer cells to 5-fluorouracil, cisplatin and camptothecin in a cell type-specific manner. Biochem Pharmacol 78(3): 249-260, 2009.
16. Srinivasan D and Plattner R: Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells. Cancer Res 66(11): 5648-5655, 2006. (Pubitemid 43927117)
17. Srinivasan D, Sims JT and Plattner R: Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival. Oncogene 27(8): 1095-1105, 2008.
18. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmen M et al: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66(3): 1630-1639, 2006. (Pubitemid 43259947)
19. Kim YH, Kwei KA, Girard L, Salari K, Kao J, Pacyna-Gengelbach M et al: Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer. Oncogene 29(10): 1421-1430, 2010.
20. Feller SM: CrK family adaptors-signalling complex formation and biological roles. Oncogene 20(44 REV. ISS. 5): 6348-6371, 2001.
21. Finn RS, Press MF, Dering J, Arbushites M, Koehler M, Oliva C et al: Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. J Clin Oncol 27(24): 3908-3915, 2009.
22. Amir E, Ocana A, Seruga B, Freedman O and Clemons M: Lapatinib and HER2 status: Results of a meta-analysis of randomized phase III trials in metastatic breast cancer. Cancer Treat Rev 36(5): 410-415, 2010.
23. Capdeville R, Buchdunger E and Zimmermann J: Matter a. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1(7): 493-502, 2002.
24. Dann SG, Selvaraj A and Thomas G: mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol Med 13(6): 252-259, 2007. (Pubitemid 46836871)
25. Inoki K, Corradetti MN and Guan K-L: Dysregulation of the TSC-mTOR pathway in human disease. Nat Genetics 37(1): 19-24, 2005.
26. Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee BN, Francis D et al: Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Ann Oncol 19(10): 1713-1719, 2008.
27. Yamasaki F, Zhang D, Bartholomeusz C, Sudo T, Hortobagyi GN, Kurisu K et al: Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Mol Cancer Ther 6(8): 2168-2177, 2007.